Search
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Synonyms: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MABProducts: Elrexfio 44 mg/1,1 ml Enjeksiyonluk Çözelti, 1 ADET, Elrexfio 76 mg/1,9 ml Enjeksiyonluk Çözelti, 1 ADETNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalIn general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. … Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents.
Products: ARSENICO TRIOSSIDO EG, Arsentrioxid Sandoz 1 mg/ml - Konzentrat zur Herstellung einer InfusionslösungThiocolchicoside
go.drugbank.com/drugs/DB11582InvestigationalThiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of _Superba gloriosa_.
Mixtures: DEKSİT 25 MG/4 MG TABLET, DEKSİT 25 MG/8 MG TABLETProducts: REUTRID 4 MG, TIOCOLCHICOSIDE EGIfosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Products: UROMIDA® 2 G, HOLOXAN®2 G.Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigationalHemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX. … The therapy involves a one-time infusion of a viral vector carrying a codon-optimized DNA sequence of the gain-of-function Padua variant of human Factor IX controlled by a liver-specific promotor 1.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalCFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. … [L6814] This drug was approved by the FDA on February 12, 2018.
Cannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalIt is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana [A32584]. … , which is a member of a large family of ion channels that are involved in the onset and progression of several types of epilepsy.
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedAs patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … The harvested product is concentrated and purified by a series of chromatography steps.
Human vaccinia virus immune globulin
go.drugbank.com/drugs/DB14112ApprovedInvestigationalwho possess high titers of anti-vaccinia virus antibody [FDA Label, A33814]. … Human vaccinia immune globulin (VIG) is a sterile solution containing the purified gamma globulin (IgG) fraction of plasma taken from healthy donors previously vaccinated with live vaccinia virus vaccine
Categories: Immunoglobulin G, Human Immunoglobulin G